| 000 | 01420 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517140149.0 | ||
| 264 | 0 | _c20171120 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a2589-0646 | ||
| 024 | 7 |
_a10.1016/j.hemonc.2016.12.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJethava, Yogesh | |
| 245 | 0 | 0 |
_aRelapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? _h[electronic resource] |
| 260 |
_bHematology/oncology and stem cell therapy _cJun 2017 |
||
| 300 |
_a47-56 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aHodgkin Disease _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xmethods |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xadverse effects |
| 650 | 0 | 4 |
_aTransplantation, Autologous _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aGuru Murthy, Guru Subramanian | |
| 700 | 1 | _aHamadani, Mehdi | |
| 773 | 0 |
_tHematology/oncology and stem cell therapy _gvol. 10 _gno. 2 _gp. 47-56 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.hemonc.2016.12.002 _zAvailable from publisher's website |
| 999 |
_c26867222 _d26867222 |
||